Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 10:2023:2305163.
doi: 10.1155/2023/2305163. eCollection 2023.

miR-31-5p as a Potential Circulating Biomarker and Tracer of Clinical Improvement for Chronic Inflammatory Demyelinating Polyneuropathy

Edyta Dziadkowiak  1 , Dagmara Baczyńska  2 , Małgorzata Wieczorek  3 , Mateusz Olbromski  4 , Helena Moreira  5 , Monika Mrozowska  4 , Sławomir Budrewicz  1 , Piotr Dzięgiel  4 , Ewa Barg  5 , Magdalena Koszewicz  1
Affiliations

miR-31-5p as a Potential Circulating Biomarker and Tracer of Clinical Improvement for Chronic Inflammatory Demyelinating Polyneuropathy

Edyta Dziadkowiak et al. Oxid Med Cell Longev. .

Abstract

Background: MicroRNAs are endogenous, small noncoding RNA molecules that play a pivotal role in the regulation of gene expression. MicroRNAs are involved in many biological processes such as proliferation, cell differentiation, neovascularization, and apoptosis. Studies on microRNA expression may contribute to a better understanding of the pathomechanism of chronic inflammatory demyelinating polyneuropathy (CIDP) and consequently enable the development of new therapeutic measures using antisense miRNAs (antagomirs). In this study, we evaluated the level of miR-31-5p in the serum of patients with CIDP and its correlation with the miR-31-5p level and clinical presentation and electrophysiological and biochemical parameters.

Methods: The study group consisted of 48 patients, mean age 61.60 ± 11.76, who fulfilled the diagnostic criteria of a typical variant of CIDP. The expression of miR-31-5p in patient serum probes was investigated by droplet digital PCR. The results were correlated with neurophysiological findings and the patient's clinical and biochemical parameters.

Results: The mean copy number of miRNA-31 in 100 μl serum was 1288.64 ± 2001.02 in the CIDP group of patients, while in the control group, it was 3743.09 ± 4026.90. There was a significant positive correlation (0.426) between IgIV treatment duration and miR-31-5p expression. Patients without IgIV treatment showed significantly lower levels of miR-31 compared to the treated group (259.44 ± 304.02 vs. 1559.48 ± 2168.45; p = 0.002). The group of patients with body weight > 80 kg showed statistically significantly lower levels of miRNA-31-5p than the patients with lower body weight (934.37 ± 1739.66 vs. 1784.62 ± 2271.62, respectively; p = 0.014). Similarly, the patients with elevated cerebrospinal fluid (CSF) protein levels had significantly higher miRNA-31-5p expression than those with normal protein levels (1393.93 ± 1932.27 vs. 987.38 ± 2364.10, respectively; p = 0.044).

Conclusion: The results may support the hypothesis that miR-31-5p is strongly involved in the autoimmune process in CIDP. The positive correlation between higher miR-31-5p levels and duration of IVIg treatment may be an additional factor explaining the efficacy of prolonged IVIg therapy in CIDP.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Histogram of miR-31-5p copies in 100 μl of serum in the patient group.
Figure 2
Figure 2
Scatter plot of the correlation between miR-31-5p expression and IgIV treatment time in CIDP patients.
Figure 3
Figure 3
Graph showing the mean copy number of miR-31-5p in the patient group—treated and untreated with IgIV—and in the control group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Liu B., Li J., Cairns M. J. Identifying miRNAs, targets and functions. Briefings in Bioinformatics . 2014;15(1):1–19. doi: 10.1093/bib/bbs075. - DOI - PMC - PubMed
    1. Liu B., Liu L., Tsykin A., Goodall G. J., Cairns M. J., Li J. Discovering functional microRNA-mRNA regulatory modules in heterogeneous data. Advances in Experimental Medicine and Biology . 2013;774:267–290. doi: 10.1007/978-94-007-5590-1_14. - DOI - PubMed
    1. Akhtar M. M., Micolucci L., Islam M. S., Olivieri F., Procopio A. D. Bioinformatic tools for microRNA dissection. Nucleic Acids Research . 2016;44(1):24–44. doi: 10.1093/nar/gkv1221. - DOI - PMC - PubMed
    1. Zhao G., Han C., Zhang Z., Wang L., Xu J. Increased expression of microRNA-31-5p inhibits cell proliferation, migration, and invasion via regulating Sp1 transcription factor in HepG2 hepatocellular carcinoma cell line. Biochemical and Biophysical Research Communications. . 2017;490(2):371–377. doi: 10.1016/j.bbrc.2017.06.050. - DOI - PubMed
    1. Kim H. S., Lee K. S., Bae H. J., et al. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithislial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget . 2015;6(10):8089–8102. doi: 10.18632/oncotarget.3512. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources